Lynparza vs Zejula

Lynparza (olaparib) and Zejula (niraparib) are both PARP inhibitors reviewed for ovarian cancer. Lynparza's indications include monotherapy for adult patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy, and maintenance treatment for adult patients with recurrent epithelial ovarian cancer. Zejula is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response to platinum-based chemotherapy.

For Lynparza, in the ITT population, the Hazard Ratio for rPFS was 0.66, with a Median rPFS of 25 months in the olaparib arm and 17 months in the placebo arm. For Zejula, the Tumour regression rate in orthotopic high-grade serous ovarian cancer PDX models (HRD positive models) was 44%.

These drugs were studied in separate trials with different designs, populations, and timepoints. The reported figures are from each drug's own review documents and are not head-to-head comparisons. Neither drug is presented as superior to the other.